Effect of aficamten on cardiac structure and function in patients with symptomatic nonobstructive hypertrophic cardiomyopathy - Results from the ACACIA-HCM trial

29 August 2026 (16:15 - 16:30)

Organised by:

Video

Slides

Sign in for access options

About the speaker

Doctor Sheila Hegde

University of Texas Southwestern Medical Center, Dallas (United States of America)

3 More presentations in this session

Presentation thumbnail

Aficamten vs. Metoprolol Monotherapy in Obstructive Hypertrophic Cardiomyopathy According to Pre-Trial Treatment in MAPLE-HCM

Doctor F. Dominguez (Madrid, ES)

Presentation thumbnail

Deep Learning Model for Detection, Phenotyping, and Left Ventricular Gradient Estimation in Hypertrophic Cardiomyopathy Using Echocardiography: Development and Multinational External Validation

Doctor F. Alenezi (Durham, US)

Presentation thumbnail

Safety and efficacy of treatment with mavacamten for up to 5 years in patients with obstructive hypertrophic cardiomyopathy: final results from MAVA-LTE

Doctor A. Owens (Philadelphia, US)

Access the full session

Session thumbnail

Late-Breaking Clinical Science: hypertrophic cardiomyopathy

The Event

Event poster

ESC Congress 2026

29 August 2026 16:15 CET

You may be interested in

Congress Presentation

ACACIA-HCM: Aficamten for symptomatic nonobstructive hypertrophic cardiomyopathy

28 August 2026

Congress Presentation

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

1 September 2024

Congress Session

Hypertrophic cardiomyopathy: from gene to treatment

31 August 2025

Congress Presentation

Efficacy and safety of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms

17 May 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources